Pharmacological  ||| S:0 E:16 ||| JJ
treatment  ||| S:16 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
fibromyalgia  ||| S:29 E:42 ||| JJ
Fibromyalgia  ||| S:42 E:55 ||| NNP
( ||| S:55 E:56 ||| -LRB-
FM ||| S:56 E:58 ||| NNP
)  ||| S:58 E:60 ||| -RRB-
is  ||| S:60 E:63 ||| VBZ
a  ||| S:63 E:65 ||| DT
common  ||| S:65 E:72 ||| JJ
syndrome  ||| S:72 E:81 ||| NN
characterised  ||| S:81 E:95 ||| NN
by  ||| S:95 E:98 ||| IN
widespread  ||| S:98 E:109 ||| JJ
pain  ||| S:109 E:114 ||| NN
and  ||| S:114 E:118 ||| CC
at  ||| S:118 E:121 ||| IN
least  ||| S:121 E:127 ||| JJS
11 ||| S:127 E:129 ||| CD
/ ||| S:129 E:130 ||| CD
18  ||| S:130 E:133 ||| CD
painful  ||| S:133 E:141 ||| JJ
tender  ||| S:141 E:148 ||| NN
points  ||| S:148 E:155 ||| NNS
that  ||| S:155 E:160 ||| WDT
requires  ||| S:160 E:169 ||| VBZ
multimodal  ||| S:169 E:180 ||| JJ
pharmacological  ||| S:180 E:196 ||| JJ
treatment  ||| S:196 E:206 ||| NN
also  ||| S:206 E:211 ||| RB
combined  ||| S:211 E:220 ||| VBN
with  ||| S:220 E:225 ||| IN
non-pharmacological  ||| S:225 E:245 ||| JJ
therapy ||| S:245 E:252 ||| NN
.  ||| S:252 E:254 ||| .
Various  ||| S:254 E:262 ||| JJ
drugs  ||| S:262 E:268 ||| NNS
currently  ||| S:268 E:278 ||| RB
are  ||| S:278 E:282 ||| VBP
available  ||| S:282 E:292 ||| JJ
to  ||| S:292 E:295 ||| TO
control  ||| S:295 E:303 ||| VB
the  ||| S:303 E:307 ||| DT
complex  ||| S:307 E:315 ||| JJ
and  ||| S:315 E:319 ||| CC
different  ||| S:319 E:329 ||| JJ
symptoms  ||| S:329 E:338 ||| NNS
reported  ||| S:338 E:347 ||| VBD
by  ||| S:347 E:350 ||| IN
patients ||| S:350 E:358 ||| NNS
.  ||| S:358 E:360 ||| .
Only  ||| S:360 E:365 ||| RB
three  ||| S:365 E:371 ||| CD
drugs  ||| S:371 E:377 ||| NNS
( ||| S:377 E:378 ||| -LRB-
duloxetine ||| S:378 E:388 ||| UH
,  ||| S:388 E:390 ||| ,
milnacipram ||| S:390 E:401 ||| NN
,  ||| S:401 E:403 ||| ,
pregabalin ||| S:403 E:413 ||| CD
)  ||| S:413 E:415 ||| -RRB-
are  ||| S:415 E:419 ||| VBP
approved  ||| S:419 E:428 ||| VBN
by  ||| S:428 E:431 ||| IN
the  ||| S:431 E:435 ||| DT
American  ||| S:435 E:444 ||| NNP
Food  ||| S:444 E:449 ||| NNP
and  ||| S:449 E:453 ||| CC
Drug  ||| S:453 E:458 ||| NNP
Administration  ||| S:458 E:473 ||| NNP
( ||| S:473 E:474 ||| -LRB-
FDA ||| S:474 E:477 ||| NNP
)  ||| S:477 E:479 ||| -RRB-
and  ||| S:479 E:483 ||| CC
none  ||| S:483 E:488 ||| NN
by  ||| S:488 E:491 ||| IN
the  ||| S:491 E:495 ||| DT
European  ||| S:495 E:504 ||| NNP
Medicines  ||| S:504 E:514 ||| NNP
Agency  ||| S:514 E:521 ||| NNP
( ||| S:521 E:522 ||| -LRB-
EMEA ||| S:522 E:526 ||| NNP
) ||| S:526 E:527 ||| -RRB-
,  ||| S:527 E:529 ||| ,
consequently ||| S:529 E:541 ||| RB
,  ||| S:541 E:543 ||| ,
off-label  ||| S:543 E:553 ||| JJ
use  ||| S:553 E:557 ||| NN
is  ||| S:557 E:560 ||| VBZ
habitual  ||| S:560 E:569 ||| VBN
in  ||| S:569 E:572 ||| IN
Europe ||| S:572 E:578 ||| NNP
.  ||| S:578 E:580 ||| .
Most  ||| S:580 E:585 ||| JJS
of  ||| S:585 E:588 ||| IN
the  ||| S:588 E:592 ||| DT
drugs  ||| S:592 E:598 ||| NNS
improve  ||| S:598 E:606 ||| VBP
only  ||| S:606 E:611 ||| RB
one  ||| S:611 E:615 ||| CD
or  ||| S:615 E:618 ||| CC
two  ||| S:618 E:622 ||| CD
symptoms ||| S:622 E:630 ||| NNS
;  ||| S:630 E:632 ||| :
no  ||| S:632 E:635 ||| DT
drug  ||| S:635 E:640 ||| NN
capable  ||| S:640 E:648 ||| NN
of  ||| S:648 E:651 ||| IN
overall  ||| S:651 E:659 ||| JJ
symptom  ||| S:659 E:667 ||| NN
control  ||| S:667 E:675 ||| NN
is  ||| S:675 E:678 ||| VBZ
yet  ||| S:678 E:682 ||| RB
available ||| S:682 E:691 ||| JJ
.  ||| S:691 E:693 ||| .
Furthermore ||| S:693 E:704 ||| RB
,  ||| S:704 E:706 ||| ,
different  ||| S:706 E:716 ||| JJ
classes  ||| S:716 E:724 ||| NNS
of  ||| S:724 E:727 ||| IN
drugs  ||| S:727 E:733 ||| NNS
with  ||| S:733 E:738 ||| IN
different  ||| S:738 E:748 ||| JJ
mechanisms  ||| S:748 E:759 ||| NNS
of  ||| S:759 E:762 ||| IN
action  ||| S:762 E:769 ||| NN
are  ||| S:769 E:773 ||| VBP
used  ||| S:773 E:778 ||| VBN
off-label ||| S:778 E:787 ||| JJ
,  ||| S:787 E:789 ||| ,
including  ||| S:789 E:799 ||| VBG
tricyclic  ||| S:799 E:809 ||| JJ
antidepressants  ||| S:809 E:825 ||| NNS
( ||| S:825 E:826 ||| -LRB-
TCAs ||| S:826 E:830 ||| NNP
) ||| S:830 E:831 ||| -RRB-
,  ||| S:831 E:833 ||| ,
selective  ||| S:833 E:843 ||| FW
serotonin  ||| S:843 E:853 ||| FW
reuptake  ||| S:853 E:862 ||| FW
inhibitors  ||| S:862 E:873 ||| FW
( ||| S:873 E:874 ||| -LRB-
SSRIs ||| S:874 E:879 ||| NNP
) ||| S:879 E:880 ||| -RRB-
,  ||| S:880 E:882 ||| ,
serotonin  ||| S:882 E:892 ||| FW
norepinephrine  ||| S:892 E:907 ||| FW
reuptake  ||| S:907 E:916 ||| FW
inhibitors  ||| S:916 E:927 ||| FW
( ||| S:927 E:928 ||| -LRB-
SNRIs ||| S:928 E:933 ||| NNP
) ||| S:933 E:934 ||| -RRB-
,  ||| S:934 E:936 ||| ,
opioids ||| S:936 E:943 ||| NN
,  ||| S:943 E:945 ||| ,
non-steroidal  ||| S:945 E:959 ||| JJ
anti-inflammatory  ||| S:959 E:977 ||| JJ
drugs  ||| S:977 E:983 ||| NNS
( ||| S:983 E:984 ||| -LRB-
NSAIDs ||| S:984 E:990 ||| NNP
) ||| S:990 E:991 ||| -RRB-
,  ||| S:991 E:993 ||| ,
growth  ||| S:993 E:1000 ||| NN
hormone ||| S:1000 E:1007 ||| NN
,  ||| S:1007 E:1009 ||| ,
corticosteroids  ||| S:1009 E:1025 ||| NN
and  ||| S:1025 E:1029 ||| CC
sedative  ||| S:1029 E:1038 ||| JJ
hypnotics ||| S:1038 E:1047 ||| NN
.  ||| S:1047 E:1049 ||| .
As  ||| S:1049 E:1052 ||| IN
no  ||| S:1052 E:1055 ||| DT
single  ||| S:1055 E:1062 ||| JJ
drug  ||| S:1062 E:1067 ||| NN
fully  ||| S:1067 E:1073 ||| RB
manages  ||| S:1073 E:1081 ||| VBZ
FM  ||| S:1081 E:1084 ||| JJ
symptoms ||| S:1084 E:1092 ||| NNS
,  ||| S:1092 E:1094 ||| ,
multicomponent  ||| S:1094 E:1109 ||| JJ
therapy  ||| S:1109 E:1117 ||| NN
should  ||| S:1117 E:1124 ||| MD
be  ||| S:1124 E:1127 ||| VB
used  ||| S:1127 E:1132 ||| VBN
from  ||| S:1132 E:1137 ||| IN
the  ||| S:1137 E:1141 ||| DT
beginning ||| S:1141 E:1150 ||| NN
.  ||| S:1150 E:1152 ||| .
Various  ||| S:1152 E:1160 ||| JJ
pharmacological  ||| S:1160 E:1176 ||| JJ
treatments  ||| S:1176 E:1187 ||| NNS
have  ||| S:1187 E:1192 ||| VBP
been  ||| S:1192 E:1197 ||| VBN
used  ||| S:1197 E:1202 ||| VBN
to  ||| S:1202 E:1205 ||| TO
treat  ||| S:1205 E:1211 ||| VB
FM  ||| S:1211 E:1214 ||| NN
with  ||| S:1214 E:1219 ||| IN
inconclusive  ||| S:1219 E:1232 ||| JJ
results ||| S:1232 E:1239 ||| NNS
,  ||| S:1239 E:1241 ||| ,
and  ||| S:1241 E:1245 ||| CC
gradually  ||| S:1245 E:1255 ||| RB
increasing  ||| S:1255 E:1266 ||| VBG
low  ||| S:1266 E:1270 ||| JJ
doses  ||| S:1270 E:1276 ||| NN
is  ||| S:1276 E:1279 ||| VBZ
suggested  ||| S:1279 E:1289 ||| VBN
in  ||| S:1289 E:1292 ||| IN
order  ||| S:1292 E:1298 ||| NN
to  ||| S:1298 E:1301 ||| TO
maximise  ||| S:1301 E:1310 ||| VB
efficacy ||| S:1310 E:1318 ||| NNS
.  ||| S:1318 E:1320 ||| .
The  ||| S:1320 E:1324 ||| DT
best  ||| S:1324 E:1329 ||| JJS
treatment  ||| S:1329 E:1339 ||| NN
should  ||| S:1339 E:1346 ||| MD
be  ||| S:1346 E:1349 ||| VB
individualised  ||| S:1349 E:1364 ||| NNS
and  ||| S:1364 E:1368 ||| CC
combined  ||| S:1368 E:1377 ||| VBN
with  ||| S:1377 E:1382 ||| IN
patient  ||| S:1382 E:1390 ||| JJ
education  ||| S:1390 E:1400 ||| NN
and  ||| S:1400 E:1404 ||| CC
non-pharmacological  ||| S:1404 E:1424 ||| JJ
therapy ||| S:1424 E:1431 ||| NN
.  ||| S:1431 E:1433 ||| .
